Chapter 24: Genitourinary Syndrome of Menopause and Vulvovaginal Atrophy

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine a condition that physically alters the architecture of the body, causes chronic pain and negatively impacts the sex lives of 75 % of the women who have it.

And now imagine that despite that massive impact, fewer than 81 % of clinicians ever even initiate a conversation about it with their patients.

I mean, it's just a massive blind spot in women's health.

So today we are pulling directly from Chapter 24 of Advanced Health Assessment of Women, Fifth Edition.

Yeah, and our mission for you today is to trace the complete clinical pathway of assessing, diagnosing, and really managing GSM.

And GSM stands for Genitourinary Syndrome of Menopause.

For decades, the medical community relied on the term Volvovaginal Atrophy, or VVA.

They did, yeah.

But back in 2014, the North American Menopause Society and the International Society for the Study of Women's Sexual Health,

they fundamentally changed that terminology.

Because VVA was just, well, it was an inherently flawed, incomplete diagnosis.

Exactly.

It completely missed the full constellation of symptoms.

I mean, VVA ignored the sexual dysfunction, the pain, and crucially, it ignored the urinary symptoms.

Right, the urinary symptoms that almost invariably accompany those vaginal changes.

Yeah.

We are talking about more than 64 million menopausal women in the United States alone who are experiencing this.

The terminology had to evolve, you know, it had to reflect the systemic nature of the syndrome.

Okay, let's unpack this.

To understand how a single condition causes such widespread genitourinary fallout, we have to look at the biological root cause.

Right, because this isn't just tissue getting older.

Exactly.

It is a profound cellular domino effect triggered by a localized starvation of estrogen.

So the vulva vaginal mucosal tissues are densely packed with estrogen receptors.

When circulating estrogen drops, the entire architecture of the vaginal epithelium just changes.

And the text uses the Vaginal Maturation Index, or VMI, to objectively measure this, right?

Can you break down that VMI for us so we can visualize what's happening to the cells?

Sure.

You can picture the vaginal lining as a wall built with four distinct layers of cells.

At the very base, you have the basal cells.

Okay, basal at the bottom.

Right.

Above those are the parabasal cells, then the intermediate cells, and finally the superficial cells sitting right on top.

So in a state of normal estrogenization, those top superficial cells are plump, they're mature, and they're just packed with glycogen.

Yes, and they constantly shed, which is actually what creates normal, healthy vaginal discharge.

But when estrogen disappears,

that architectural wall essentially collapses, doesn't it?

It totally collapses.

Those plump superficial cells and the intermediate cells fail to mature, and they just vanish.

The mucosal lining thins out drastically.

Meaning the parabasal cells, which are supposed to remain deep within the tissue bed, suddenly become the exposed, highly vulnerable top layer of the vagina.

Exactly.

Which triggers a massive chemical shift.

When those superficial cells vanish, well, their glycogen goes right with them.

Oh, wow.

And without glycogen, the local bacterial environment is completely upended, right?

Specifically regarding lactobacilli.

Yeah, the lactobacilli, it's actually very much like a sourdough fermentation process.

Oh, I love this analogy.

In sourdough, lactic acid bacteria consume carbohydrates and produce acid, creating an environment so acidic that mold and competing bacteria just cannot survive.

Right.

That mechanism is identical to the vaginal microbiome.

Normal lactobacilli consume the glycogen from the shedding superficial cells, and they convert it into lactic acid.

Which keeps the vaginal pH inherently hostile to invaders, usually tightly controlled between 4 .0 and 4 .6.

Exactly.

But when estrogen drox and the glycogen disappears, the lactobacilli starve, the lactic acid production halts, and the vaginal pH inevitably rises.

So it becomes much more alkaline.

And without that acidic defense mechanism, it's like a bustling city losing its local security force, right?

That is a perfect way to look at it.

Nuisance elements, or pathogenic bacteria like Gardnerella or Streptococci, can easily colonize the tissue.

It is a complete structural and chemical breakdown.

And it's really crucial for you, the listener, to recognize that this breakdown isn't exclusively a post -menopausal phenomenon.

Box 24 .1 in the text lists a bunch of non -age -related causes.

Yeah, it's not just natural menopause.

You might see a 28 -year -old postpartum patient who is exclusively breastfeeding.

Right, because of that precipitous drop in estrogen after delivery.

Exactly.

Combined with the antagonistic action of prolactin during lactation, that can induce severe GSM symptoms.

Or you might be treating, say, a 40 -year -old breast cancer survivor on anti -estrogen medications like tamoxifen.

Or aromatase inhibitors.

Heavy smoking, chemotherapy, pelvic radiation, they all trigger the exact same cellular disappearance and pH shift.

So if we have a patient sitting in the exam room, whether she's 65 and post -menopausal or 30 and postpartum, her subjective complaints are going to directly mirror that cellular pathology.

Absolutely.

The hallmark vulvovaginal symptoms reported in the history will be profound dryness, a total lack of lubrication during arousal, and dyspareunia.

Painful intercourse.

And you really need to differentiate the type of dyspareunia during your history taking You do.

The pain might be superficial right at the entroitus because the mucosa has thinned and narrowed.

Or she might describe deep dyspareunia.

Right, because the entire vaginal canal has physically shortened and lost its elasticity.

The text mentions a fascinating clinical pearl here regarding this narrowing and shortening the use it or lose it phenomena.

Yes, that is a direct clinical pearl from the text.

If a patient maintains regular sexual relations through perimenopause and beyond, she is significantly less likely to experience these severe atrophic changes.

Wow.

So maintaining that activity actually helps prevent the tissue changes.

It does.

The mechanical action of penetrative intercourse or even just the use of dilators promotes sustained blood flow to the genital area.

And that continuous vascular engorgement helps maintain the elasticity and health of the tissues even as systemic estrogen levels begin to wane.

Exactly.

But wait, I want to push back a little and connect the history back to the name change

OK, let's do it.

If the underlying mechanism is a lack of glycogen in the vaginal wall, why is a patient complaining about frequent UTIs, dysuria, and a dropped bladder?

Well, you have to look at the embryology.

The lower urinary tract, specifically the urethra and the trigone of the bladder, develops from the exact same embryologic tissue as the lower vagina.

The urogenital sinus.

Exactly.

And because of this shared origin, the squamous epithelium of the urethra and the bladder and the trigone are also highly concentrated with estrogen receptors.

Oh, I see.

So the urinary tract is literally starving for estrogen right alongside the reproductive tract.

You got it.

The urethral lining thins out, it loses its protective nicosal seal, and becomes highly susceptible to irritation and ascending bacteria.

The entire pelvic region is experiencing the fallout.

Right.

And while taking this history, we have to listen carefully for red flags.

Like vaginal bleeding or spotting?

I mean, if a patient reports spotting after intercourse, our first instinct might be to attribute it to the sheer fragility of those exposed parabessel cells.

But we cannot just assume it's tissue friability, assuming spotting is just atrophy is a dangerous clinical trap.

Right.

You must investigate the source to rule out endometrial pathology.

Exactly.

The textbook highlights a really critical clinical guideline from ACOG.

When a postmenopausal woman presents with bleeding, you order a transvaginal ultrasound.

And if the ultrasound reveals an endometrial echo of 4 millimeters or less, then an endometrial biopsy is generally not required.

Because a lining that thin indicates generalized atrophy, whereas a thicker stripe would raise immediate suspicion for endometrial hyperplasia or malignancy.

Precisely.

And if her urinary symptoms include hematuria, you know, gross or microscopic blood in the urine, that warrants a dedicated urologic workup to rule out bladder cancer.

Regardless of how classic her GSM symptoms appear.

Exactly.

Okay, so once the subjective history paints a picture of estrogen loss and red flags are addressed, it's time to verify it with a physical exam.

And here's where it gets really interesting.

It really does.

There's a specific diagnostic finding highlighted in box 24 .2 called the sticky glove sign.

Yes, the sticky glove sign.

Because the vulvar tissue has completely lost its natural secretions and moisture, the examiner's glove will create intense friction.

It literally adheres to the labial tissue during palpation.

Right.

That temporary adhesion is actually considered a diagnostic hallmark of GSM.

Wow.

And visually, if we look at box 24 .2 and the figures in the text, what are we looking for?

Well, the external genitalia will show significant volume loss.

The subcutaneous fat depletes.

The labia majora minora sort of flatten out.

Yeah, and the labia minora may even fuse together over the clitoris, causing the clitoris to retract beneath the prepuce.

You'll also note that the pubic hair becomes sparse and loses its coarse texture.

Okay, and moving internally to the vaginal wall, the tissue will appear pale because the vascularity has significantly decreased.

Right.

It often looks shiny, incredibly friable, and easily traumatized by the speculum.

We might even see patechial spots like micro hemorrhages into the surface and small ulcerations.

Yeah.

But the most striking structural change is the complete loss of rugae.

The rugae are the corrugated folds of the vaginal wall that allow the tissue to expand and stretch.

Right.

Right?

So in GSM, those folds completely flatten out.

And do.

It is basically the physiological equivalent of an accordion losing its pleats.

I mean, an accordion without pleats cannot expand.

That's a great analogy.

A vaginal canal without rugae physically cannot accommodate penetration, which perfectly explains the severe, deep dyspareunia the patient described in her history.

And we also need to examine the urethral metis, tying back to those urinary complaints.

Figure 24 .5 in the chapter illustrates a urethral caruncle.

Right.

Because the urethral mucosa is thinning and retracting, you might see a small, friable, red berry -type polyp protruding directly from the metis.

And if you visualize a caruncle, you have found the physical source of her dysuria and localized spotting.

Exactly.

Then we finish the physical assessment with the bimanual exam.

Given that the entire region is estrogen -starved, the uterus and cervix are going to physically shrink.

The cervix can flatten so much that the oz becomes difficult to identify just by touch.

Yeah.

The uterus will be palpably smaller.

But this brings up a non -negotiable safety rule for the bimanual exam in menopausal women.

Oh, about the ovaries.

Right.

The ovaries deprived of estrogen stimulation should be atrophic and non -palpable.

Meaning, if you can feel an ovary in a postmenopausal patient,

a timely and thorough workup for ovarian malignancy is immediately indicated.

Immediately.

Okay, so we have our history and we visualize the tissue changes.

But a pale, friable vagina with a high PAs and particular micro hemorrhages doesn't just point to GSM, it perfectly mimics certain infections.

It does.

Table 24 .1 provides the differential diagnosis litmus test for us.

We established that GSM causes an elevated vaginal pH typically greater than 5 .0.

Right.

So if you swab that tissue, confirm the elevated pH, and then perform a KOH whiff test, the amine test, it should be negative in a patient with GSM.

Because even though the pH is high, the specific anaerobic bacteria that cause bacterial vaginosis aren't the ones dominating the flora.

Exactly.

BV produces volatile amines that release a fishy odor when mixed with potassium hydroxide.

GSM does not produce those amines.

But wait, you have to be really vigilant about clinical traps here, right?

Things that will artificially skew your pH reading during the exam?

Oh, absolutely.

Box 24 .3 explicitly warns about this.

For example, recent intercourse can throw off your assessment because semen is highly alkaline with a pH of 7 or higher.

And menses, cervical mucus, even the standard lubricant you apply to your speculum, can falsely elevate the vaginal pH.

Even residual tap water on your instruments can do it.

That's wild.

Okay, so let's say we control for all those variables.

The pH is genuinely 5 .5, the KOH is negative, but the patient has pervasive petechial spots on her cervix and vaginal walls.

Then we have to consider trichomoniasis.

It is the great mimicker of GSM.

Wait, really?

In postmenopausal women?

Yes.

The prevalence of trichomoniasis in women older than 40 can reach up to 15%.

It is a protozoan parasite that can remain completely asymptomatic for decades, only to suddenly reactivate during peri - or postmenopause as the local immune defenses wane.

And because the petechiae from a trichomoniasis infection, often called a strawberry cervix, look nearly identical to the microhemorrhages caused by severe tissue atrophy,

microscopy is an absolute requirement.

It really is.

You cannot rely on visual inspection alone.

You must look at a wet mount under the microscope.

And if your office microscope skills are out of practice, or the sample is equivocal with too much cellular debris, then you are required to run a point -of -care test like the Affirm or Awesome test.

Assuming a friable, bleeding vagina is simply menopause without ruling out trichomoniasis is a massive liability.

Okay, so once we have conclusively ruled out the mimickers and locked in the diagnosis of GSM, we transition to management.

We know the exact clinical picture now.

Right, the cellular architecture is compromised, the pH is high, and the tissue is deeply dehydrated.

The North American Menopause Society recommends a step -wise approach here, starting with non -hormonal over -the -counter interventions.

First -line management involves vaginal moisturizers applied internally three times a week to maintain baseline tissue hydration, coupled with dedicated lubricants used specifically during sexual penetration to minimize friction and prevent micro tears.

But the clinical pearl here is that you cannot just tell your patient to grab whatever is on the shelf at the pharmacy.

Right, because of the osmolarity.

The World Health Organization actually has strict guidelines regarding the osmolarity of these products.

They recommend using products with an osmolarity of less than 1200 milliosmoles per kilogram of water.

Yes.

Understanding the physics of osmosis is critical here.

The patient's epithelial cells are already compromised and dehydrated.

So she applies a hyperosmotic lubricant one with a very high concentration of sleuth's osmotic pressure,

will actively pull water out of her vaginal cells and into the vaginal lumen.

Exactly, which dehydrates the tissue even further and causes intense burning.

Conversely, a severely hypoosmotic product will force water into the cells until they swell and lies or rupture.

You must recommend physiologically balanced products.

Okay, but moisturizers and balanced lubricants treat the mechanical friction.

They do nothing to reverse the underlying absence of estrogen.

That's true.

When first -line therapies fail to improve the patient's quality of life, we have to move to FDA -approved prescription therapies.

And the gold standard for localized GSM is topical vaginal estrogen, right?

It is.

If the patient is only suffering from vulvovaginal symptoms and does not have systemic vasomotor issues like hot flashes,

local topical therapy is strongly preferred over systemic hormone replacement.

Because topical estrogen physically rebuilds the vaginal maturation index.

Yes.

It forces the parabasal cells back down, matures the superficial cells, restores the glycogen, feeds the lactobacilli and drops the pH back to the normal 4 .0 range.

We have several delivery methods to consider, though, and patient adherence is heavily dictated by the method we choose.

Very heavily.

Conjugated equine estrogen or estradiol creams are effective, usually dosed daily for two weeks, then twice weekly.

But patients routinely abandon them because creams are notoriously messy.

Right.

We can prescribe low -dose vaginal tablets, but those require a hard plastic applicator.

And if the patient has severe intraudal stenosis, inserting that applicator will cause the exact pain we are trying to treat.

Which is why the newer delivery systems are so vital.

There is a soft gel vaginal insert that does not require an applicator at all.

The patient just inserts it manually with her finger.

It adheres cleanly to the mucosa and dissolves.

Alternatively, there is a 90 -day estrogen ring.

You place it in the upper third of the vaginal vault, and it steadily releases a microdose of 7 .5 micrograms of estradiol every day for three months.

But this brings us to the most significant hurdle in prescribing these treatments.

This Gary FDA boxed warning.

Yes.

When a patient picks up her low -dose vaginal estrogen at the pharmacy, the box will be about systemic risks, cardiovascular disease, stroke, and breast cancer.

Which requires aggressive, proactive patient counseling.

That boxed warning is a class effect label mandated by the FDA.

It's really a remnant of the massive Women's Health Initiative study that looked at high -dose systemic oral hormone therapy.

But research shows low -dose topical estrogen is completely different.

Decades of subsequent pharmacokinetic research have conclusively proven that low -dose localized vaginal estrogen does not significantly increase systemic serum estradiol.

The hormone stays in the vaginal tissue.

It doesn't flood the bloodstream.

Exactly.

The serum levels remain safely within the normal post -menopausal range.

Because the systemic absorption is negligible, you do not even need to prescribe a concomitant progestogen for women with a uterus.

And the safety profile is so robust that both NM's and ACOG have formally endorsed the use of low -dose vaginal estrogen for survivors of breast cancer.

Yes, even those actively taking aromatase inhibitors, provided it is done in shared decision -making with their oncologist.

But if we fail to explain the context of that boxed warning before the patient leaves the clinic, she will read the insert, panic, and throw the medication in the trash.

She absolutely will.

So what if a patient has a hard contraindication to estrogen, or just simply refuses it?

Well, we have two major alternative pharmacologic pathways.

The first is DHEA, prescribed under the brand name Prasterone.

Oh, right.

This is a daily vaginal insert containing a steroid hormone.

Yes, and the brilliant mechanism of Prasterone is intracranology.

The DHEA is absorbed into the vaginal cells and is locally converted into both estradiol and testosterone inside the cell itself.

Oh, wow.

And because this conversion happens intracellularly, it does not carry the FDA boxed warning for systemic estrogen risks.

Exactly.

No boxed warning.

The second alternative is an oral medication called ospemethene, which is a selective estrogen receptor modulator, or CIRM.

CIRMS are fascinating because they change their behavior depending on the target tissue.

Ospemethene acts as an estrogen agonist in the vaginal mucosa.

Stimulating the cells, increasing glycogen, and relieving dyspareunia.

Right.

However, in other parts of the body, it can act differently.

Because it is a systemic oral medication, its most common side effect is triggering vasomotor symptoms.

Meaning it can actually induce or worsen hot flashes.

Yeah, unfortunately.

Beyond pharmacology, there are non -pharm options and mechanical interventions.

We discussed the use it or lose it concept.

Right.

For patients who have avoided penetrative intercourse for years due to pain, we need to prescribe the use of vaginal dilators.

Graduated dilators used consistently with a physiological lubricant safely stretch the contracted tissue.

Vibrators are also clinically recommended, right?

Yes, to stimulate localized nerve endings and force blood flow into the atrophic capillary beds.

But energy -based devices like lasers, we need to be careful there.

You must approach energy -based devices with extreme caution.

You will see marketing for vaginal lasers or radio frequency rejuvenation clinics.

But the text is definitive on this.

As of 2021, the FDA has not approved these devices for the treatment of GSM.

Right.

While proponents claim they induce thermal damage to stimulate collagen remodeling, there are documented reports of severe adverse events.

Like vaginal scarring, lacerations, and worsening intractable dyspareunia.

Exactly.

It can cause real harm.

Now, if a patient is experiencing unremitting pelvic pain that localized estrogen and dilators cannot resolve, we have to look past the mucosa and look at the musculature.

Because years of anticipating pain during intercourse causes hypertonic dysfunction in the pelvic floor.

Exactly.

Referring the patient to a specialized pelvic floor physical therapist for internal myofascial release is an incredible underutilized asset for breaking that chronic pain cycle.

So what does this all mean?

Well, it brings us back to the statistic we opened with.

75 % of these women are experiencing an active detriment to their sex lives, their relationships, and their self -image.

And fewer than 81 % of providers are asking the necessary questions to uncover it.

The challenge laid out by this chapter is for you to be the clinician who breaks that silence.

You have the pathophysiology, the differential diagnoses, and the treatment pathways.

But you also need to know your limitations.

If resolving the tissue atrophy doesn't resolve the profound psychosocial distress, you must be prepared to refer your patient to an AACT certified sex therapist.

A licensed mental health professional trained specifically in sexual dysfunction.

Because treating GSM isn't just about restoring plump superficial cells or normalizing a pH balance.

It is about understanding the deep, undeniable connection between cellular architecture and a woman's fundamental quality of life.

You are utilizing your assessment skills not just to diagnose a syndrome, but to restore a patient's comfort and agency within her own body.

A warm thank you from the Last Minute Lecture team for joining us on this deep dive.